vimarsana.com

Page 3 - Diffuse Large Lymphoma Research Foundation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL) - Press Release

Company Announcement Based on the topline results from the EPCORE™ NHL-1 clinical trial, Genmab and AbbVie will engage global regulatory authorities t

New jerseyUnited statesMohamed zakiGlobal oncology developmentMacrophage properties journal of immunology baltimoreExchange commissionHodgkin lymphoma research foundationUs national library of medicineDevelopment of novel antiDiffuse large lymphoma research foundationCompany announcementChief executive officerVice presidentAllergan aestheticsAnnual reportY shaped genmab

Genmab and AbbVie Announce Topline Results for Epcoritamab

Company Announcement Based on the topline results from the EPCORE™ NHL-1 clinical trial, Genmab and AbbVie will engage global regulatory authorities to.

United statesNorth chicagoNew jerseyLiz sheaIlke limoncuMabel martinezKalvebod bryggeMarisol peronMohamed zakiAndrew carlsenGlobal oncology developmentMacrophage properties journal of immunology baltimoreExchange commissionHodgkin lymphoma research foundationUs national library of medicineDevelopment of novel anti

Genmab A/S: Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)

Company Announcement Based on the topline results from the EPCORE NHL-1 clinical trial, Genmab and AbbVie will engage global regulatory authorities to discuss next steps Data from the clinical

New jerseyUnited statesLiz sheaIlke limoncuMabel martinezMarisol peronMohamed zakiAndrew carlsenGlobal oncology developmentMacrophage properties journal of immunology baltimoreExchange commissionHodgkin lymphoma research foundationUs national library of medicineDevelopment of novel antiGlobal investor relations communicationsCompany announcement

AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)

/PRNewswire/ AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) today announced topline results from the first cohort of the EPCORE™ NHL-1 phase 1/2 clinical.

New jerseyUnited statesMohamed zakiMacrophage propertiesj immunolExchange commissionHodgkin lymphoma research foundationUs national library of medicineDevelopment of novel antiDiffuse large lymphoma research foundationCompany announcementLargeb cellAllergan aestheticsPrivate securities litigation reform actQuarterly reportsAnnual reportY shaped genmab

vimarsana © 2020. All Rights Reserved.